官方服务：
资源简介：
Costs of anti-TB drugs in USD.
应用场景：
创建时间：
2020-12-01
相关数据集
Results of scenario analyses for cCRT population.
ObjectiveThe effectiveness of sugemalimab vs. placebo in post-chemoradiotherapy patients with locally advanced, unresectable stage III NSCLC has been demonstrated and approved by China National Medica
Figshare2023-06-01 更新30
Table_1_Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials.DOC
BackgroundSacubitril-valsartan was recommended for heart failure (HF) and proven cost-effective in HF. Recently, sacubitril-valsartan has been recommended to treat hypertension by the Chinese expert c
NIAID Data Ecosystem20
Data Sheet 3_Economic evaluation of intravenous iron formulations for patients with iron deficiency anemia: a systematic review.pdf
BackgroundVarious intravenous iron formulations show great promise in the treatment of iron deficiency anemia (IDA), and economic evaluation results are becoming increasingly important as criteria for
NIAID Data Ecosystem10
Characteristics of the study participants.
India has a high burden of Tuberculosis (TB), accounting for a significant portion of global cases. While efforts are being made to engage the formal private sector in the National TB Elimination Prog
NIAID Data Ecosystem30
Cost-Effectiveness Results by Gender and Genotype, Triple Therapy with Telaprevir.
(ICER: incremental cost-effectiveness ratios. dominated: strategy costs more but achieves less QALY than the previous strategy or a combination of strategies).
NIAID Data Ecosystem20
